# EDGAR Filing Document

**Accession Number:** 0002029777
**File Stem:** 0000905148-26-001871
**Filing Date:** 2026-4
**Character Count:** 17481
**Document Hash:** eb0814b135b71077549afafc8ec65877
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000905148-26-001871.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0000905148-26-001871

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260427

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACHIEVE LIFE SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000949858
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954343413
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-45969
- **FILM NUMBER:** 26902269

**BUSINESS ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021
- **BUSINESS PHONE:** 425-686-1500

**MAIL ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ONCOGENEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20080821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SONUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19950825
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** venBio Global Strategic Fund V, L.P.
- **CENTRAL INDEX KEY:** 0002029777

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 595
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-522-0100

**MAIL ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 595
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158

## Exhibit 99.1

------

#### Exhibit 99.1

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of ACHIEVE LIFE SCIENCES, INC., dated as of April 27, 2026, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

---

| | | |
|:---|:---|:---|
| Dated: April 27, 2026 |  |  |
|  | VENBIO GLOBAL STRATEGIC FUND V, L.P. | VENBIO GLOBAL STRATEGIC FUND V, L.P. |
|  | By: | VENBIO GLOBAL STRATEGIC GP V, LLC<br> General Partner |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |
|  | VENBIO GLOBAL STRATEGIC GP V, LLC | VENBIO GLOBAL STRATEGIC GP V, LLC |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |

---

---

| | |
|:---|:---|
| \* | \* |
| Aaron Royston<br> \* | Aaron Royston<br> \* |
| Corey Goodman | Corey Goodman |
| \* | \* |
| Richard Gaster | Richard Gaster |
| \*By: | /s/ David Pezeshki |
|  | David Pezeshki |
|  | As attorney-in-fact |

---

This Agreement was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, copies of which are attached as Exhibit 99.2 and Exhibit 99.3.

------

## Exhibit 99.2

Exhibit 99.2

#### POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Pezeshki his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 10<sup>th</sup> day of February, 2017.

---

| |
|:---|
| /s/ Aaron Royston |
| Aaron Royston<br>|

---

---

| |
|:---|
| /s/ Corey Goodman |
| Corey Goodman<br>|

---

---

| |
|:---|
| /s/ Robert Adelman |
| Robert Adelman |

---

------

## Exhibit 99.3

#### EXHIBIT 99.3<br>

#### POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Pezeshki his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 21st day of April, 2026.

---

| |
|:---|
| /s/ Richard Gaster<br>|
| Richard Gaster<br>|

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ACHIEVE LIFE SCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**David Pezeshki**<br>1700 Owens Street<br>Suite 595<br>San Francisco CA 94158<br>(415) 800-0800

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/15/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**venBio Global Strategic Fund V, L.P.** | Name of reporting person<br>**venBio Global Strategic Fund V, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10737317.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10737317.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10737317.00** | Aggregate amount beneficially owned by each reporting person<br>**10737317.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**venBio Global Strategic GP V, LLC** | Name of reporting person<br>**venBio Global Strategic GP V, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10737317.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10737317.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10737317.00** | Aggregate amount beneficially owned by each reporting person<br>**10737317.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
ACHIEVE LIFE SCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
22722 29th Drive SE, Suite 100, Bothell, WA, 98021

**Item 4. Purpose of Transaction**

The response to Item 3 of this Schedule 13D is incorporated herein by reference.

The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. 

Dr. Royston, who is a member of General Partner V, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Royston, may engage in discussions from time to time with the Board, the Issuer's management, or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the "Securities"); (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy, or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated transactions, or other methods.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, each of the Reporting Persons may be deemed to beneficially own 10,737,317 shares of Common Stock, or approximately 9.99% of the shares of Common Stock outstanding. This amount consists of (i) 5,914,720 shares of Common Stock directly held by Fund V and (ii) 4,822,597 shares of Common Stock that Fund V has the right to acquire within 60 days upon the exercise of Common Warrants, subject to the 9.99% Ownership Limitation.

The foregoing amount excludes 1,092,123 shares of Common Stock underlying Common Warrants that Fund V does not have the right to acquire within 60 days upon the exercise of Common Warrants due to the 9.99% Ownership Limitation.

The beneficial ownership percentage reported herein is based on the sum of (i) 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 24, 2026, (ii) 49,418,069 shares of Common Stock that were issued to Investors in connection with the Private Placement that closed on April 17, 2026, as reported in the Issuer's current report on Form 8-K filed with the SEC on April 16, 2026, and (iii) 4,822,597 shares of Common Stock that Fund V has the right to acquire within 60 days upon the exercise of Common Warrants, subject to the 9.99% Ownership Limitation, which shares are added to the total shares of Common Stock outstanding for purposes of calculating the Reporting Persons' beneficial ownership percentage in accordance with Rule 13d-3(d)(1)(i) under the Act.

**(b)**
The Reporting Persons share the power to vote or direct the voting of, and the power to dispose or direct the disposition of, the 10,737,317 shares of Common Stock that Fund V directly beneficially owns.

**(c)**
The response to Item 3 of this Schedule 13D is incorporated herein by reference.

Except as set forth herein, the Reporting Persons have not engaged in any transactions with respect to the Common Stock during the 60 days prior to the date of filing of this Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The response to Item 3 of this Schedule 13D is incorporated herein by reference.

In connection with the Private Placement, the Issuer and the Investors, including Fund V, entered into a Registration Rights Agreement, dated as of April 15, 2026 (the "Registration Rights Agreement), providing for the registration for resale of the shares of Common Stock, Pre-Funded Warrant Shares, and Common Warrant Shares. The Issuer has agreed to prepare and file a registration statement (the "Registration Statement") with the SEC promptly, and in any event within 30 days of the closing of the Private Placement, and to use its reasonable best efforts to have the Registration Statement declared effective within 75 days following the initial filing date of the Registration Statement. 

The Issuer has granted the Investors customary indemnification rights in connection with the Registration Rights Agreement. The Investors have also granted the Issuer customary indemnification rights in connection with the Registration Statement. 

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, a form of which is attached as an exhibit to this Schedule 13D and is incorporated herein by reference. 

Except as otherwise described herein, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) among the Reporting Persons, or between such persons and any other person, with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** venBio Global Strategic Fund V, L.P.

**Signature:** /s/ David Pezeshki

**Name/Title:** David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members of the General Partner

**Date:** 04/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** venBio Global Strategic GP V, LLC

**Signature:** /s/ David Pezeshki

**Name/Title:** David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members

**Date:** 04/27/2026